Inside Trade: Michael Kauffman Sold 10,000 Shares of Karyopharm Therapeutics Inc. (KPTI); Eii Capital Management Has Cut Its Kilroy Rlty (KRC) Stake

Karyopharm Therapeutics Inc’s Chief Executive Officer Michael Kauffman made a sale of 10,000 shares of the public company in a broker transaction dated March 8, 2018. The sold shares were unloaded at the average stock price of $16.1, for an aggregate trade of $161,463. In the last month, he also unloaded 20,000 shares that are worth $272,920 USD. The chance of this transaction staying undiscovered is quite small because it’s new, with the Chief Executive Officer now holding 1.32 million shares – that is 2.67% of the Company’s market capitalization.

Eii Capital Management Inc decreased Kilroy Rlty Corp (KRC) stake by 66.91% reported in 2017Q3 SEC filing. Eii Capital Management Inc sold 82,906 shares as Kilroy Rlty Corp (KRC)’s stock declined 5.77%. The Eii Capital Management Inc holds 40,994 shares with $2.92M value, down from 123,900 last quarter. Kilroy Rlty Corp now has $6.99B valuation. The stock increased 0.14% or $0.1 during the last trading session, reaching $69.34. About 419,819 shares traded. Kilroy Realty Corporation (NYSE:KRC) has risen 21.14% since March 9, 2017 and is uptrending. It has outperformed by 4.44% the S&P500.

Analysts await Kilroy Realty Corporation (NYSE:KRC) to report earnings on April, 25. They expect $0.90 EPS, up 11.11% or $0.09 from last year’s $0.81 per share. KRC’s profit will be $90.66 million for 19.26 P/E if the $0.90 EPS becomes a reality. After $0.85 actual EPS reported by Kilroy Realty Corporation for the previous quarter, Wall Street now forecasts 5.88% EPS growth.

Investors sentiment decreased to 0.92 in 2017 Q3. Its down 0.32, from 1.24 in 2017Q2. It is negative, as 20 investors sold KRC shares while 76 reduced holdings. 28 funds opened positions while 91 raised stakes. 94.47 million shares or 2.33% less from 96.72 million shares in 2017Q2 were reported. Swiss Retail Bank accumulated 164,311 shares. Northwestern Mutual Wealth accumulated 0% or 40 shares. Victory Capital Mgmt Inc holds 0.12% or 764,252 shares in its portfolio. Ftb Advsr accumulated 118 shares or 0% of the stock. Schwab Charles Mngmt invested 0.06% of its portfolio in Kilroy Realty Corporation (NYSE:KRC). Advsrs Asset invested in 0.01% or 11,327 shares. Alliancebernstein Lp holds 0.01% or 114,318 shares. Comerica Bankshares holds 80,803 shares. Rafferty Asset Mgmt reported 16,106 shares or 0.03% of all its holdings. Canada Pension Plan Investment Board invested 0.03% of its portfolio in Kilroy Realty Corporation (NYSE:KRC). Amp Cap Invsts Ltd holds 0.57% of its portfolio in Kilroy Realty Corporation (NYSE:KRC) for 1.44M shares. Sumitomo Mitsui Asset stated it has 0.01% in Kilroy Realty Corporation (NYSE:KRC). Landscape Capital Management Ltd Liability has 33,300 shares for 0.24% of their portfolio. Dimensional Fund Advisors LP owns 1.38M shares. Dynamic Capital Mgmt Ltd holds 0.1% or 5,121 shares.

Among 16 analysts covering Kilroy Realty (NYSE:KRC), 5 have Buy rating, 1 Sell and 10 Hold. Therefore 31% are positive. Kilroy Realty had 42 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Kilroy Realty Corporation (NYSE:KRC) has “Neutral” rating given on Friday, December 15 by JP Morgan. The stock has “Neutral” rating by Robert W. Baird on Monday, January 8. The firm has “Buy” rating given on Monday, May 2 by Deutsche Bank. BMO Capital Markets maintained Kilroy Realty Corporation (NYSE:KRC) on Wednesday, October 25 with “Buy” rating. As per Wednesday, August 16, the company rating was downgraded by Bank of America. The firm earned “Hold” rating on Thursday, February 15 by RBC Capital Markets. As per Wednesday, October 21, the company rating was downgraded by Bank of America. The firm has “Buy” rating given on Monday, September 18 by Stifel Nicolaus. The stock of Kilroy Realty Corporation (NYSE:KRC) earned “Underperform” rating by Credit Suisse on Friday, July 31. The company was downgraded on Thursday, October 22 by Stifel Nicolaus.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $25’s average target is 51.88% above currents $16.46 stock price. Karyopharm Therapeutics Inc. had 29 analyst reports since August 11, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Hold” rating in Tuesday, March 15 report. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Overweight” rating given on Monday, March 14 by JP Morgan. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by H.C. Wainwright on Tuesday, December 12. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by Cantor Fitzgerald on Friday, June 23. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by H.C. Wainwright on Thursday, September 8. The firm has “Buy” rating given on Monday, September 11 by Jefferies. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. The company was reinitiated on Wednesday, November 15 by H.C. Wainwright. RBC Capital Markets maintained the shares of KPTI in report on Thursday, November 2 with “Buy” rating. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Monday, October 16 by RBC Capital Markets.

The stock increased 2.94% or $0.47 during the last trading session, reaching $16.46. About 248,402 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since March 9, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Since September 11, 2017, it had 0 insider purchases, and 21 sales for $1.66 million activity. Mirza Mansoor Raza sold $40,000 worth of stock. Another trade for 10,000 shares valued at $147,872 was sold by Shacham Sharon. Primiano Christopher Brett also sold $18,000 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Monday, October 2. Another trade for 10,000 shares valued at $125,048 was made by Kauffman Michael on Wednesday, February 7.

Investors sentiment decreased to 1.56 in Q3 2017. Its down 0.94, from 2.5 in 2017Q2. It is negative, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported. Goldman Sachs has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Alliancebernstein Ltd Partnership reported 43,430 shares. Fmr Ltd Llc invested in 0.01% or 4.01M shares. Iguana Management Limited Liability has invested 2.45% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). American Grp Inc Incorporated holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 22,659 shares. Barclays Public Limited Co holds 0% or 7,157 shares. Blackrock invested in 3.04 million shares or 0% of the stock. Wellington Group Llp reported 0.02% stake. 26,084 were accumulated by Manufacturers Life Insur The. Geode Cap Mngmt Limited Company holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 265,121 shares. Art Advsr Lc holds 0.01% or 26,552 shares in its portfolio. Royal National Bank & Trust Of Canada holds 3,669 shares. Deutsche Financial Bank Ag, a Germany-based fund reported 162,265 shares. Price T Rowe Md invested in 13,895 shares. California State Teachers Retirement Sys stated it has 54,693 shares or 0% of all its holdings.